Rongtuan Lin
Overview
Explore the profile of Rongtuan Lin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
107
Citations
5986
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kurmasheva N, Said A, Wong B, Kinderman P, Han X, Rahimic A, et al.
Nat Commun
. 2024 Dec;
15(1):10698.
PMID: 39702301
No abstract available.
2.
Kurmasheva N, Said A, Wong B, Kinderman P, Han X, Rahimic A, et al.
Nat Commun
. 2024 May;
15(1):4096.
PMID: 38750019
The presence of heterogeneity in responses to oncolytic virotherapy poses a barrier to clinical effectiveness, as resistance to this treatment can occur through the inhibition of viral spread within the...
3.
Yi Q, Han X, Yu H, Chen H, Qiu D, Su J, et al.
Oncogene
. 2024 Mar;
43(20):1522-1533.
PMID: 38532114
Androgen deprivation therapies (ADT) are the mainstay treatments for castration-resistant prostate cancer (CRPC). ADT suppresses the androgen receptor (AR) signaling by blocking androgen biosynthesis or inhibiting AR with antiandrogens that...
4.
Wang Z, Pan Q, Ma L, Zhao J, McIntosh F, Liu Z, et al.
Virus Res
. 2023 Jun;
334:199164.
PMID: 37379907
Vaccines and drugs are two effective medical interventions to mitigate SARS-CoV-2 infection. Three SARS-CoV-2 inhibitors, remdesivir, paxlovid, and molnupiravir, have been approved for treating COVID-19 patients, but more are needed,...
5.
Yi Q, Liu W, Seo J, Su J, Alaoui-Jamali M, Luo J, et al.
Mol Cancer Ther
. 2023 May;
22(5):570-582.
PMID: 37139712
The current mainstay therapeutic strategy for advanced prostate cancer is to suppress androgen receptor (AR) signaling. However, castration-resistant prostate cancer (CRPC) invariably arises with restored AR signaling activity. To date,...
6.
Liu Z, Larocque E, Xie Y, Xiao Y, Lemay G, Peloponese J, et al.
Front Microbiol
. 2022 Dec;
13:988944.
PMID: 36532440
Human T-cell leukemia virus type 1 is the causative agent of HTLV-1-associated myelopathy/tropical spastic paraparesis and adult T-cell leukemia-lymphoma (ATL). The HTLV-1 basic leucine zipper factor (HBZ) has been associated...
7.
Xu Z, Choi J, Dai D, Luo J, Ladak R, Li Q, et al.
Proc Natl Acad Sci U S A
. 2022 Jul;
119(32):e2204539119.
PMID: 35878012
Viruses evade the innate immune response by suppressing the production or activity of cytokines such as type I interferons (IFNs). Here we report the discovery of a mechanism by which...
8.
Zhao J, Zhang G, Zhang Y, Yi D, Li Q, Ma L, et al.
Antiviral Res
. 2021 Nov;
196:105209.
PMID: 34801588
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative agent of Coronavirus Disease 2019 (COVID-19) pandemic. Despite intensive and global efforts to discover and develop novel antiviral therapies, only Remdesivir...
9.
Huang K, Huang L, Zhang X, Zhang M, Wang Q, Lin H, et al.
Acta Trop
. 2021 Sep;
224:106145.
PMID: 34562426
Cerebral malaria (CM) is the most severe neurological complication caused by Plasmodium falciparum infection. The accumulating evidence demonstrated that mast cells (MCs) and its mediators played a critical role in...
10.